



MAGELLAN RX MANAGEMENT  
**MEDICAL PHARMACY**  
**TREND REPORT™**



2022 TWELFTH EDITION

# THE MAGELLAN RX MANAGEMENT MEDICAL PHARMACY TREND REPORT IS ONE OF A KIND.

This industry-leading report is the only detailed source analyzing:



**MEDICAL BENEFIT  
CLAIM TRENDS**



**DATA BENCHMARKS IN  
MEDICAL PHARMACY**



**MEDICAL BENEFIT DRUG  
MANAGEMENT STRATEGIES**

Our MRx Medical Pharmacy experts are dedicated to keeping you informed so you can make better healthcare decisions. Dive deeper into the trends, forecasts, and insights in this year's report.

# TABLE OF CONTENTS

---

2022 Methodology and Demographics	3
Executive Summary	4
Medical Pharmacy Trend Drivers	6
Medical Pharmacy Trends	7
Medical Benefit Categories	11
Biosimilar Trends	17
Medical Pharmacy Management	18
Appendix	23
Glossary	49

---

## Contributors

**LAURA WALTERS, R.PH.**  
Director, Specialty Clinical Solutions

**PRERAK PARIKH, PHARM.D.**  
Director, Specialty Clinical Solutions

**ANDY KILLPACK, PHARM.D.**  
Director, Specialty Clinical Solutions

**JONATHAN GUNTER, FSA**  
Pharmacy Actuarial Consultant

**HEATHER OZHOGIN, FSA**  
Senior Director, Underwriting

**DAVID ECKWRIGHT, PHARM.D., MHI, CSP**  
Senior Director, Specialty Analytics and Informatics

**KRISTEN REIMERS, R.PH.**  
Senior Vice President, Specialty Clinical Solutions

**KAYLA HIRSCH**  
Vice President, Marketing

**MICHELLE BOOTH, PHARM.D.**  
Senior Director, Specialty Clinical Solutions

**YUQIAN LIU, PHARM.D.**  
Senior Director, Specialty Clinical Solutions

**JACOB LARUE, PHARM.D.**  
Senior Director, Specialty Clinical Solutions

**MARIAM ALBOUSTANI, PHARM.D.**  
Director, Specialty Clinical Solutions

**SNEHA SHARMA, PHARM.D.**  
Director, Specialty Clinical Solutions

**AMY WARE, PHARM.D.**  
Director, Specialty Clinical Solutions

**KATIE LOCKHART, MS**  
Senior Manager, Forecasting and Pharmacoeconomics

**DANNY MELSON**  
Senior Analyst, Forecasting and Pharmacoeconomics

---

## Payer Advisory Board

**MARTIN BURRUANO, R.PH.**  
Vice President, Pharmacy Services  
Independent Health

**PATRICK GILL, R.PH.**  
Director of Pharmacy, Commercial  
Horizon BlueCross BlueShield of New Jersey

**CARLY RODRIGUEZ, PHARM.D., FAMCP**  
Vice President and Chief Pharmacy Officer  
Moda Health

**GARY TERESO, PHARM.D.**  
Director of Pharmacy  
Health New England

---

© 2022 Magellan Rx Management, LLC. Magellan Rx Management 2022 Medical Pharmacy Trend Report™ is published in conjunction with D Custom. All rights reserved. All trademarks are the property of their respective owners. The content—including text, graphics, images, and information obtained from third parties, licensors, and other material (“content”)—is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Figures may be reprinted with the following citation: Magellan Rx Management Medical Pharmacy Trend Report™, Twelfth Edition, © 2022. Used with permission.”

# 2022 METHODOLOGY AND DEMOGRAPHICS

The 2022 edition of the Magellan Rx Medical Pharmacy Trend Report was developed utilizing medical pharmacy industry standard methodologies, calculations, guidance from medical drug management experts, and feedback from previous trend reports.


This report includes a combination of primary and secondary research methodologies to deliver a comprehensive view of payer perceptions and health plan actions related to provider-administered infused or injected drugs paid under the medical benefit, also referred to as medical benefit drugs. These medical benefit drugs are commonly used to treat diseases such as cancer, autoimmune disorders, and immunodeficiencies.

## Health Plan Claims Data

Medical benefit drug utilization and trend data were collected through secondary analyses of commercial, Medicaid, and Medicare Advantage health plan medical paid claims data for the most recent calendar years. Claims data was analyzed for medical pharmacy utilization across **1,010** healthcare common procedure coding system (HCPCS) and several outpatient sites of service.\* Most analyses compared calendar years 2020 and 2021. In some cases, the past four years were analyzed to show a longer period of year-over-year spend and trend. All data includes allowed amount costs directly from health plans for medical drugs only. Administration codes were analyzed separately and discussed on page 10 and in the appendix, Figures 126 and 127.


\*Vaccines and radiopharmaceuticals were excluded. Drugs administered in the hospital inpatient setting are not included in any analyses.

### CLAIMS DATA BY REGION *Figure 1*




## Payer Survey


### RESPONDENT SAMPLE *Figure 2*



### RESPONDENT PLAN SIZE *Figure 3*



### GEOGRAPHIC DISPERSION OF LIVES *Figure 4*



### MEDICAL BENEFIT DRUG EXAMPLES FOR THERAPEUTIC CLASSES *Figure 5*

Drug Category	Example Drugs*
Antihemophilic Factors	Advate, Recombinate, Xyntha
Asthma	Fasenra, Nucala, Xolair
Biologic Drugs for Autoimmune Disorders	Cimzia, Entyvio, Orencia, Remicade
Botulinum Toxins	Botox, Dysport, Xeomin
Immune Globulin	Gammagard, Gamunex, Octagam
Multiple Sclerosis	Lemtrada, Ocrevus, Tysabri
Oncology	Avastin, Cyramza, Erbitux, Vectibix
Oncology Immunotherapy	Bavencio, Imfinzi, Keytruda, Opdivo
Oncology Support	Antiemetics, CSFs, ESAs
Ophthalmic Injections	Avastin, Eylea, Lucentis
Viscosupplementation	Euflexxa, Gel-One, Hyalgan, Orthovisc

\*Not an inclusive list

# EXECUTIVE SUMMARY

● Commercial ● Medicare ● Medicaid ∕ Forecast

The past four years have been unprecedented in healthcare. There has been tremendous change due to the introduction of gene therapies, biosimilar market entrants, and a global pandemic, all dramatically influencing trends for medical benefit drugs.


In 2021, medical benefit drug trends were significantly less than they were pre-pandemic. Historically, as reported in previous Medical Pharmacy Trend Reports, the norm was a year-over-year PMPM trend ranging from 6% to 17% across all three lines of business. In 2020 and 2021, medical benefit drugs had dramatic decreases in overall utilization. Looking forward, spend is forecasted to increase over the next three years, mainly driven by oncology and high-cost, novel molecular entities in the rare disease category.

Uptake in biosimilar use and the 2020 launch of Darzalex Faspro, a provider-administered subcutaneous formulation of Darzalex IV, significantly influenced the growth in trends across all three lines of business (see Figure 6).


Growth in commercial outpatient hospital spend accounted for more than half of the 3.2% positive trend due to it being a higher-cost site of service and less than typical utilization of the lower-cost drugs (see Figure 8 and appendix, Figure 75). Trends for the highest-cost drugs were 30% or greater (see Figure 13).

Medicaid trend was flat, mainly due to the negative trend in oncology offsetting the trend increase in rare disease.


2018-2025 PMPM TRENDS & FORECAST *Figure 7*



2021 TOP DRUG SPEND DRIVERS *Figure 6*




2018-2021 HOSPITAL OUTPATIENT % OF TOTAL CLAIMS VOLUME *Figure 8*



# EXECUTIVE SUMMARY



● Commercial ● Medicare ● Medicaid

## 2019-2021 MEDICAL PHARMACY UTILIZATION (CLAIMS/1K MEMBERS) *Figure 9*



COVID-19 restrictions resulted in a sharp drop in utilization of less-expensive drugs, while utilization of more-expensive therapies remained constant. Drug utilization remained consistent in oncology but dropped in oncology support. Overall utilization began to rebound in 2021; however, pre-pandemic levels were not reached.

## CLAIM VOLUME TREND *Figure 10*



# MEDICAL PHARMACY TREND DRIVERS

● Commercial ● Medicare ● Medicaid

## 2021 TREND CONTRIBUTORS *Figure 11*

Claim Volume	Allowed per Claim Trend	Overall PMPM Trend
+5.6%	-2.3%	+3.2%
+1.1%	+1.5%	+2.7%
-2.6%	+2.6%	0.0%

## Volume vs. Cost Contributors


In the commercial space, claim volume had the highest influence on aggregate trend due to more patients receiving medical drug therapy in 2021 vs. 2020, whereas in government programs, allowed per-claim costs had the largest impact on aggregate trend, due to patients receiving more of the higher-cost medical drug therapies in 2021 vs. 2020.




## Trends in 2021

The medical drug space saw some exciting new therapies enter the market in 2020, impacting drug trends in 2021. FDA fast-track approvals increased by almost 30%,\* and high-cost orphan drugs saw a record high number of approvals in 2020, with a 40% increase over 2019.\*\* The top 20 drugs had spend trends of 30-34%, driven by utilization increases for commercial and Medicare and driven evenly by both cost and utilization for Medicaid.

## 2021 TREND FOR TOP 20 DRUG CATEGORIES\*\*\* *Figure 12*



## 2021 TREND FOR TOP 20 DRUGS\*\*\* *Figure 13*



\*<https://www.fda.gov/drugs/nda-and-bla-approvals/fast-track-approvals>

\*\*<https://www.accessdata.fda.gov/scripts/opdlisting/oopd/listResult.cfm>

\*\*\*Rank based on PMPM spend includes positive or negative changes 2020-21.

# MEDICAL PHARMACY TRENDS

## COMMERCIAL

Commercial trends for top therapies and drugs were volatile in 2021, with growth in new indications and drugs and decreases where biosimilars impact the market. For the first time in this report's history, Avastin, Herceptin and Rituxan, are not in the top 10 drugs, with the biosimilars of Mvasi and Kanjinti increasing in market share.

Non-oncology trend outpaced total oncology trend, driven by large spend increases in rare disease and multiple sclerosis. Over 2021, the biggest individual drug contributors to the rise in non-oncology PMPM were Ocrevus, at \$0.24, and Tepezza, at \$0.38.


Oncology and supportive agents combined spend retained just under 50% of the total PMPM, with new products and expanded indications.

Overall utilization of hematology products for the commercial population went down -2.6% in 2021. Cost trends were also negative, -5.1%, in 2021 and had a much larger influence on the universal trend. Ultomiris spend was driven by increased utilization. However, Ultomiris cost decreases helped to mitigate the \$0.05 PMPM increase. Decrease in overall Soliris spend was heavily driven by utilization drop-off, which resulted in it not appearing in the Top 25 drug PMPM (see Figure 79).

Keytruda moved to the top drug in 2020 and remained there in 2021 with a 22% trend. Currently, there are 31 FDA-approved indications over 16 oncology types plus two tumor-agnostic cancers. Trend forecasts predict growth at a slower rate over the next few years.


Commercial trend is forecasted to increase approximately 5% to 6% annually after experiencing another year of slow growth, with a 3.2% overall trend for medical drugs, due to lingering COVID-19 impacts (see Figure 7).

2021 TOTAL ONCOLOGY VS. NON-ONCOLOGY SPEND Figure 14




Due to rounding, totals may not add up accurately.

2020-2021 TOP 10 DRUG THERAPY CATEGORIES BY PMPM SPEND Figure 15



2021 TOP 10 MEDICAL BENEFIT DRUGS BY SPEND Figure 16



\*New market entry.

2021 UNCLASSIFIED CODE AND SELECTED DRUGS BY ALLOWED AMOUNT PMPM Figure 17

J3490	Avastin, Bridion, Gattex, Ultiva	\$0.16
C9399	Cosela, Rybrevant, Rylaze	\$0.04
J3590	Dupixent, Saphnelo, Uplizna	\$0.02
J9999	Monjuvi, Rybrevant, Zynlonta	\$0.01

There are other unclassified codes that combined account for roughly \$0.01-\$0.02 PMPM for each line of business.



# MEDICAL PHARMACY TRENDS

## MEDICARE


The overall Medicare PMPM trend jumped to 2.7%, a significant spike from the -0.9% trend in 2020, to which several factors contributed (see Figure 7).

In 2020, oncology claim volume fell over 6% and non-oncology fell slightly more than 12%. Additionally, during COVID-19 lockdowns, utilization of less-expensive drugs dropped dramatically. As lockdown restrictions eased in 2021, utilization and drug mix began progressing toward a positive trend.

Oncology was the primary category driving trend and accounted for 59% of the total PMPM spend, 20% of which consisted of Keytruda, Opdivo, and Tecentriq.


The forecast anticipates that Medicare trend will start to normalize at a 5% to 6% year-over-year increase through 2025.

### 2021 TOTAL ONCOLOGY VS. NON-ONCOLOGY SPEND Figure 18




Due to rounding, totals may not add up accurately.

### 2020-2021 TOP 10 DRUG THERAPY CATEGORIES BY PMPM SPEND Figure 19



### 2021 TOP 10 MEDICAL BENEFIT DRUGS BY SPEND Figure 20



### 2021 UNCLASSIFIED CODE AND SELECTED DRUGS BY ALLOWED AMOUNT PMPM Figure 21

<b>C9399</b>	Cosela, Pepaxto, Rybrevant	\$0.11
<b>J3490</b>	Recarbrio, Veklury	\$0.05
<b>J3590</b>	Cosentyx, Cutaquig, Dupixent	\$0.03
<b>J9999</b>	Monjuvi	\$0.02

There are other unclassified codes that combined account for roughly \$0.01-\$0.02 PMPM for each line of business.

# MEDICAL PHARMACY TRENDS

## MEDICAID

The overall Medicaid PMPM trend was flat, likely due to lingering COVID-19 impact.

Oncology medical benefit spend continued to trend down in 2020 and 2021 and in Medicaid is forecasted to decrease slightly again in 2022 (see Figure 7).


Rare disease PMPM trend had the most significant increase, 41%, driven by Zolgensma and Tepezza utilization.

Remicade PMPM trend decreased 17%, impacted by increased prescribing of biosimilar products.

Unclassified Code utilization was minimal, with only J3490 having spend attributable to PMPM, driven mostly by sufentanil and medroxyprogesterone products.


We expect Medicaid to adopt a positive trend going forward through 2025, driven by increased utilization, new therapies, rare disease, and oncology.

### 2021 TOTAL ONCOLOGY VS. NON-ONCOLOGY SPEND Figure 22




Due to rounding, totals may not add up accurately.

### 2020-2021 TOP 10 DRUG THERAPY CATEGORIES BY PMPM SPEND Figure 23



### 2021 TOP 10 MEDICAL BENEFIT DRUGS BY SPEND Figure 24



### 2021 UNCLASSIFIED CODE AND SELECTED DRUGS BY ALLOWED AMOUNT PMPM Figure 25

J3490	Depo-Provera, Cosela, Sufentanil Citrate	\$0.33
C9399	None with impact	\$0.00
J3590	None	\$0.00
J9999	None with impact	\$0.00

There are other unclassified codes that combined account for roughly \$0.01-\$0.02 PMPM for each line of business.

# MEDICAL PHARMACY TRENDS

## Administrative Code Reimbursement

The spend impact on the administration of medical benefit drugs was highly dependent on the site of service (SOS). Administration of chemotherapy treatment was two to three times more costly in the hospital outpatient setting compared to the physician office across all lines of business, while coming in as fourth-highest spend for Medicaid and top spend for commercial and Medicare.

In Medicare, the administration of intravitreal/ophthalmic agents injections closely follows chemotherapy treatment, as ophthalmic injections were a high-volume category for Medicare members.

Medicaid's highest-spend administrative code, immunization administration, had little to no spend in the hospital, indicating that almost all administration was in the physician office.

### 2020 TOP ADMINISTRATIVE CODES BY PMPM FOR HOSPITAL OUTPATIENT AND PHYSICIAN OFFICE

#### COMMERCIAL

CPT® Code & Description	Physician	Hospital	Total PMPM
<b>96413</b> Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$0.36	\$0.75	<b>\$1.11</b>
<b>96365</b> Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$0.12	\$0.42	<b>\$0.54</b>
<b>96372</b> Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$0.32	\$0.11	<b>\$0.44</b>
<b>90460</b> Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered	\$0.42	\$0.00	<b>\$0.42</b>
<b>96375</b> Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug	\$0.05	\$0.36	<b>\$0.40</b>

#### MEDICARE

CPT® Code & Description	Physician	Hospital	Total PMPM
<b>96413</b> Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$0.37	\$1.36	<b>\$1.73</b>
<b>67028</b> Intravitreal injection of a pharmacologic agent (separate procedure)	\$0.95	\$0.17	<b>\$1.13</b>
<b>20610</b> Under general introduction or removal procedures on the musculoskeletal system	\$0.56	\$0.17	<b>\$0.73</b>
<b>96365</b> Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$0.12	\$0.58	<b>\$0.70</b>
<b>96374</b> Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$0.01	\$0.64	<b>\$0.66</b>

#### MEDICAID

CPT® Code & Description	Physician	Hospital	Total PMPM
<b>90460</b> Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered	\$0.50	\$0.03	<b>\$0.52</b>
<b>96367</b> Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour	\$0.04	\$0.17	<b>\$0.21</b>
<b>96372</b> Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$0.08	\$0.03	<b>\$0.11</b>
<b>96413</b> Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$0.03	\$0.08	<b>\$0.11</b>
<b>96374</b> Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$0.00	\$0.08	<b>\$0.09</b>

Due to rounding, totals may not add up accurately.

# MEDICAL BENEFIT CATEGORIES

## Rare Disease\*

Rare diseases and conditions affect an estimated 25 to 30 million people in the U.S. While drug development to manage these conditions has progressed, approved treatments are available for around 7% of the approximately 7,000 rare diseases that have been identified.\*\* While the data shows a significant impact, it is likely just the tip of the iceberg. The largest current impact of this category is in the Medicaid sector, where cost per claim is much higher with a larger prevalence of rare disease medical drug utilization, given younger age demographic in this line of business. The forecast predicts a growth of almost double by 2025 for Medicaid.


Rare disease drugs included in this report are Amondys 45, Brineura, Evkeeza, Exondys 51, Gamifant, Luxturna, Onpattro, Radicava, Reblozyl, Spinraza, Tepezza, Uplizna, Vyondys 53, and Zolgensma. Not all rare disease drugs had utilization (see appendix, Figures 83-85).

\*Rare disease includes subcategories CNS rare disease and all other rare diseases.


\*\*"Rare Diseases." National Institutes of Health, Feb. 11, 2020, <https://www.nih.gov/about-nih/what-we-do/nih-turning-discovery-into-health/rare-diseases>.

● Commercial ● Medicare ● Medicaid ▨ Pipeline\*

2020-2021 PMPM TREND *Figure 26*




2021 % OF MEDICAL DRUG SPEND *Figure 27*



2021 COST PER CLAIM *Figure 28*



4-YEAR PMPM FORECAST *Figure 29*



\*Pipeline is reported only for those with a total impact of at least \$300M per year.

# MEDICAL BENEFIT CATEGORIES

## Biologic Drugs for Autoimmune Disorders (BDAIDs)\*


BDAIDs spend has increased only slightly year over year across all lines of business. The relatively flat trend here seems to be a result of a good balance between novel autoimmune drugs with increased cost and modest uptake in lower-cost biosimilars.

One of the key drivers in this category is Entyvio, which accounts for 27% of the total BDAID PMPM spend in the commercial market and 20% in both Medicare and Medicaid. Based on ICD 10 codes, Inflectra and Truxima were also among the top 10 trend drivers in this category and had positive utilization trends of 49% and 343%, respectively, in the commercial market.


\*Includes ankylosing spondylitis, Crohn's disease/ulcerative colitis, psoriasis/psoriatic arthritis, rare autoinflammatory conditions, rheumatoid arthritis, and systemic lupus erythematosus.

● Commercial ● Medicare ● Medicaid ▨ Pipeline\*

2020-2021 PMPM TREND *Figure 30*



2021 % OF MEDICAL DRUG SPEND *Figure 31*



2021 COST PER CLAIM *Figure 32*



4-YEAR PMPM FORECAST *Figure 33*



\*Pipeline is reported only for those with a total impact of at least \$300M per year.

# MEDICAL BENEFIT CATEGORIES

## Immune Globulin\*

The trend in the commercial and Medicaid spaces remained relatively consistent but saw a decrease in percent of medical drug spend, from 9% in 2020 for each to 5.9% and 3.5% in 2021, respectively (see Figures 15 and 23).

The Medicare trend rose in 2021 by 14.4%, with a projected total PMPM increase of 4.8% by 2025.


The cost per claim in the commercial space was 163% higher than Medicare and 149% higher than Medicaid due to drug mix and reimbursement differences across the lines of business.

While the trend for this class is relatively flat, management remains essential due to the potential for off-label use, dosing escalation, and drug wastage.


\*Includes both IV and SC immune globulin

● Commercial ● Medicare ● Medicaid ▨ Pipeline\*

2020-2021 PMPM TREND *Figure 34*



2021 % OF MEDICAL DRUG SPEND *Figure 35*



2021 COST PER CLAIM *Figure 36*



4-YEAR PMPM FORECAST *Figure 37*



\*Pipeline is reported only for those with a total impact of at least \$300M per year.

# MEDICAL BENEFIT CATEGORIES

## Oncology\*

Oncology spend continues to rise in the commercial and Medicare markets, with a modest decline in Medicaid.

Prior to 2020, oncology spend trended in the double digits. Due to the introduction of biosimilars, generic launches, and depressed medical services during COVID-19, oncology spend grew at a slower pace and is forecasted to climb 5% to 8% year-over-year from 2022 through 2025 (see Figure 41).


Oncology drugs such as Keytruda, Darzalex Faspro, Mvasi, Ruxience, and Trazimera are the key trend drivers across all lines of business, with biosimilars driving most of the utilization trend.

The more recent approvals of cell and gene therapies being delivered in the inpatient setting are not influencing trends in this year's report. Biosimilar-preferencing strategies and value-based arrangements for cell and gene therapies will be the key to offset some of the growing oncology costs.


\*Does not include oncology-support drugs such as antiemetics, colony-stimulating factors, gastrointestinal: chemoprotectants, and erythropoiesis-stimulating agents.

● Commercial ● Medicare ● Medicaid ▨ Pipeline\*

2020-2021 PMPM TREND Figure 38



2021 % OF MEDICAL DRUG SPEND Figure 39



2021 COST PER CLAIM Figure 40



4-YEAR PMPM FORECAST Figure 41



\*Pipeline is reported only for those with a total impact of at least \$300M per year.

# MEDICAL BENEFIT CATEGORIES

## Oncology Support


Oncology support PMPM trended down across all lines of business and is forecasted to decline even further in the upcoming years. This can be partly attributed to increased utilization of relatively less toxic immunotherapy options in lieu of cytotoxic chemotherapy.

In addition, the continued uptake of the biosimilars in the CSF category has largely contributed to the declining trend. Not to be overlooked, Retacrit had 70% of market share for the Epoetin Alfa drug group (see Figure 123). Since 2019, oncology-support biosimilars have contributed to an impressive estimated 5.7% reduction in total oncology support PMPM spend in commercial markets. The estimated reduction in total oncology support PMPM spend for the government markets were 0.1% for Medicare and 3.1% for Medicaid (see appendix, Figures 121-123).


\*Includes antiemetics, colony-stimulating factors, gastrointestinal: chemoprotectants, and erythropoiesis-stimulating agents.

● Commercial ● Medicare ● Medicaid ▨ Pipeline\*

2020-2021 PMPM TREND Figure 42




2021 % OF MEDICAL DRUG SPEND Figure 43



2021 COST PER CLAIM Figure 44



4-YEAR PMPM FORECAST Figure 45



\*Pipeline is reported only for those with a total impact of at least \$300M per year.



# MEDICAL BENEFIT CATEGORIES

## Hematology\*

Hematology made an appearance as a category to watch in 2021. Its contribution to the total medical drug spend is smaller than other categories', but the future PMPM impact is one to keep on the radar.

It is interesting to see a drop in 2020-21 PMPM for commercial only. This can be attributed to two main reasons:

1. Overall utilization was lower.
2. Drugs that made up the largest portion of PMPM spend saw decreasing cost trends.


While utilization is low, spend can be impactful, requiring unique management strategies involving expert specialists to understand the individualized care needed to treat these special disease states.

Ultomiris IV and Soliris are currently leading the charge for spend in this category, which continues to grow, with recently approved drugs such as Ultomiris SC and Zynteglo. Soliris has a biosimilar in the pipeline forecasted for approval in 2025. Continued research for therapies in sickle cell disease provides hope for new therapy options where little exists today. The story promises to be very interesting over the next few years.


\*Hematology drugs included in this report are Andexxa, Enjaymo, Kcentra, Adakveo, ATryn, Desferal, Nandrolone Decanoate, Neumega, Nplate, Panhematin, Pentaspan, Refludan, RiaSTAP, Soliris, and Ultomiris. Not all hematology drugs had utilization (see Figures 95-97).

● Commercial ● Medicare ● Medicaid ≡ Pipeline\*

2020-2021 PMPM TREND *Figure 46*




2021 % OF MEDICAL DRUG SPEND *Figure 47*



2021 COST PER CLAIM *Figure 48*



4-YEAR PMPM FORECAST *Figure 49*



\*Pipeline is reported only for those with a total impact of \$300M.

# BIOSIMILAR TRENDS\*

Payers and providers are embracing biosimilars in oncology, as evidenced by bevacizumab and trastuzumab biosimilars capturing more than 80% of the market share compared to their reference products in 2021, with expected continued strong growth in the years to come for all three.


Similar uptake is seen in the short-acting CSF class, where Zarxio and Nivestym account for 92% of utilization, primarily due to the early introduction of biosimilars in this category. The shifts are less dramatic for long-acting CSF products, where biosimilar uptake has been slower, and Neulasta (SC & Onpro) still holds 73% of the market share in 2021. As a reference, please see market share trends in appendix, pages 39 and 40, as well as appendix, Figures 121 and 122. Since 2019, oncology biosimilars have contributed to a dramatic estimated reduction of 7% total oncology PMPM spend for commercial markets. The estimated reduction in total oncology PMPM spend for government markets were 1.6% in Medicare and 0.5% in Medicaid.

Remicade is the only reference product holding around 90% market share in 2021 despite the early entry of its biosimilars. Infliximab biosimilars have resulted in lower unit cost and stronger rebates for the reference product, thus influencing payer preferencing strategies. Biosimilar competition has resulted in a drop of 17% in ASP for Remicade in 2020 and 12% in 2021.


The continued growth of biosimilars warrants tactful utilization management strategies, which should help decrease trend in oncology, oncology support, and autoimmune drug categories.

\*See appendix, Figures 119-125.

**BEVACIZUMAB MARKET SHARE\*\*** Figure 50




**INFLIXIMAB MARKET SHARE** Figure 51




\*\*Bevacizumab and Rituximab market shares reflect oncology indications only. Only drugs with \$0.01 PMPM or greater were included in market share analysis.

**TRASTUZUMAB MARKET SHARE** Figure 52



**RITUXIMAB MARKET SHARE\*** Figure 53



# MEDICAL PHARMACY MANAGEMENT


## Payer Survey: Top Management Trends

Oncology was the top concern for payers in 2021, and rightly so, with 17 new oncology products approved by the FDA in 2021 alone. Gene therapy remains a top concern for approximately half of payers, a drop from previous years. The exploding pipeline, medical benefit spend, and trend are also top of mind for payers (see Figure 54).


Oncology continued to be a top spend category with an ever-evolving landscape. Brand products frequently received expanded-indication approvals. The rise of oncology as a concern for payers coincided with the increase in use of oncology-related management strategies.

High-cost therapies will continue to increasingly impact the financials of the U.S. health system, thus requiring unique strategies that positively impact the total cost of quality care (see Figures 56 and 57).


### TOP CONCERNS FOR MEDICAL PHARMACY *Figure 54*



### UTILIZATION MANAGEMENT TOOLS *Figure 55*



### CATEGORY MANAGEMENT *Figure 56*



### Unique Category Management *Figure 57*



Self-reported payer survey data may not add up to 100%.

# MEDICAL PHARMACY MANAGEMENT

## Payer Survey: Cost Share and Reimbursement Trends

Cost share and reimbursement trends saw a developing strategy from 2020 to 2021 that included varying cost share by the site of service, which may help with member steering and acceptance of changes in the site of care. Undoubtedly, the pandemic contributed to this as well.

More than half of the surveyed payers utilized single case agreements with providers or bundled rates for reimbursing chimeric antigen receptor T-cell therapy (CAR-T) products. With the potential increase in the utilization of CAR-T products due to expanded indications and new product approvals, payers need to consider implementing different reimbursement strategies.

The expanding availability of biosimilar products led to more product-preferencing strategies in oncology than in the past. To encourage biosimilar use, payers reported using innovative approaches such as lowering cost share to the patient as well as specific provider and patient education.

More than half of the surveyed payers experienced savings using programs such as dose optimization, vial rounding, and weight-based dosing (see Figures 61-63).

### Varied Cost Share

% of payers

**34%** varied member cost share by site of service (n=13)

**32%** varied cost share by drug (n=10)

**17%** varied cost share by indication (n=6)

### 2021 COST SHARE Figure 58

#### COMMERCIAL (n=39)



Average Rates: \$49 Copay | 20% Coinsurance

#### MEDICARE (n=23)




Average Rates: 20% Coinsurance

### CAR-T REIMBURSEMENT Figure 59

% of payers (n=39)

- Single-case agreement
- Bundled rates (drug bundled with hospitalization)
- Standing contracts with providers
- Wholesale acquisition cost
- Other
- Don't know




### BIOSIMILAR REIMBURSEMENT Figure 60


% of payers (n=38)

- Other ASP plus x%
- AWP minus x%
- Medicare model (WAC+6% then ASP+6% of reference product's ASP)
- Other strategy (varies, other rebates, exclusive infusion company)
- Maximum allowable cost (reimbursement for reference and biosimilars is equivalent)
- Comparable drug profit to reference product

Reimbursement model aligned across all drugs (n=32)



Reimbursement model not aligned across all drugs (n=6)



Self-reported payer survey data may not add up to 100%.


# MEDICAL PHARMACY MANAGEMENT

## Payer Survey: Program Trends

### DOSE-OPTIMIZATION PROGRAM *Figure 61*

Consolidates a patient's regimen into fewer units.

● Yes, mandatory ● Yes, voluntary ● No



**96%**  
Immune Globulin  
(n=24)

**67%**  
Antihemophilic Factor  
(n=24)

**67%**  
BDAIDs  
(n=24)

● Yes ● No ● Don't know

Experienced Savings (n=24)




**15%**  
Average Savings (n=14)<sup>†</sup>



### VIAL-ROUNDING PROCEDURE *Figure 62*

Identifies injectable drug waste that occurs due to limited vial size availability from drug manufacturers.

● Yes, mandatory ● Yes, voluntary ● No



**65%**  
Immune Globulin  
(n=23)

**65%**  
BDAIDs  
(n=23)

**57%**  
Oncology  
(n=23)

● Yes ● No ● Don't know

Experienced Savings (n=25)




**12%**  
Average Savings (n=14)<sup>†</sup>



### WEIGHT-BASED DOSING *Figure 63*

Applies personalized dosing to high-cost agents to achieve the most appropriate dosing while maintaining safety and efficacy.

● Yes, mandatory ● Yes, voluntary ● No



**86%**  
Keytruda  
(n=14)

**86%**  
Opdivo  
(n=14)

**57%**  
Bavencio  
(n=14)

**43%**  
Imfinzi  
(n=14)

● Yes ● No ● Don't know

Experienced Savings (n=14)



**13%**  
Average Savings (n=8)<sup>†</sup>




<sup>†</sup>Savings self-reported.  
Self-reported payer survey data may not add up to 100%.

# MEDICAL PHARMACY MANAGEMENT


## Payer Survey: Site-of-Service (SOS) Trends

### SOS PROGRAM *Figure 64*

% of lives ● Yes, mandatory ● Yes, voluntary ● No



### ADMINISTERED SOS PROGRAMS *Figure 65*




**93%** of lives in a plan that varied cost share by SOS experienced positive outcomes.

**20%** is the average perceived savings for SOS programs.†


### ONCOLOGY DRUGS IN SOS PROGRAM *Figure 66*

% of payers (n=11)




### SOS PROGRAM POPULATION *Figure 67*

% of payers (n=27)




### CHANGING MANAGEMENT TO HOME FOR COVID-19 *Figure 68*



### WHERE MEMBERS SHIFTED *Figure 69*

average % of members (n=27)




†Savings self-reported.  
Self-reported payer survey data may not add up to 100%.


# MEDICAL PHARMACY MANAGEMENT

## Payer Survey: Innovation & Forward-Looking Trends

### NDC, FORECASTING AND QUALITY *Figure 70*




### USE OF NDC DATA *Figure 71*




Self-reported payer survey data may not add up to 100%.

### USE OF FORECASTING DATA *Figure 72*




**91%** of those surveyed receive forecasting data annually or quarterly. (n=35)

### MOST USEFUL PIPELINE INFORMATION *Figure 73*



### MRX PIPELINE DRUG OUTLOOK THROUGH 2022<sup>1</sup> *Figure 74*



<sup>1</sup>MRx Pipeline Report October 2022. <https://www1.magellanrx.com/publications/mrx-pipeline/>.

<sup>2</sup>Data provided by Evaluate Ltd. EvaluatePharma®

# APPENDIX

MEDICAL PHARMACY ALLOWED AMOUNT PMPM 2018-2021 *Figure 75*

	2018	2018-19 % Change	2019	2019-20 % Change	2020	2020-21 % Change	2021
<b>COMMERCIAL</b>							
Home Infusion	\$3.54	▲ 16.6%	\$4.13	▲ 8.8%	\$4.49	▲ 1.8%	\$4.57
Hospital OP	\$15.38	▲ 13.5%	\$17.45	▼ -2.3%	\$17.06	▲ 5.3%	\$17.95
Physician Office	\$12.97	▲ 10.8%	\$14.37	▲ 1.1%	\$14.53	▲ 1.3%	\$14.72
<b>Total</b>	<b>\$31.89</b>	<b>▲ 12.7%</b>	<b>\$35.95</b>	<b>▲ 0.4%</b>	<b>\$36.08</b>	<b>▲ 3.2%</b>	<b>\$37.25</b>
<b>MEDICARE</b>							
Home Infusion	\$2.56	▲ 2.1%	\$2.61	▼ -0.3%	\$2.60	▲ 0.8%	\$2.62
Hospital OP	\$20.08	▲ 17.8%	\$23.65	▲ 4.3%	\$24.67	▲ 9.8%	\$27.09
Physician Office	\$30.76	▲ 6.6%	\$32.78	▼ -4.8%	\$31.22	▼ -2.8%	\$30.34
<b>Total</b>	<b>\$53.39</b>	<b>▲ 10.6%</b>	<b>\$59.05</b>	<b>▼ -0.9%</b>	<b>\$58.49</b>	<b>▲ 2.7%</b>	<b>\$60.06</b>
<b>MEDICAID</b>							
Home Infusion	\$1.00	▲ 33.3%	\$1.34	▲ 16.8%	\$1.56	▲ 6.1%	\$1.66
Hospital OP	\$9.62	▲ 9.9%	\$10.57	▲ 1.9%	\$10.77	▲ 3.9%	\$11.19
Physician Office	\$3.39	▲ 32.9%	\$4.51	▲ 1.2%	\$4.57	▼ -11.4%	\$4.04
<b>Total</b>	<b>\$14.01</b>	<b>▲ 17.2%</b>	<b>\$16.42</b>	<b>▲ 2.9%</b>	<b>\$16.90</b>	<b>▶ 0.0%</b>	<b>\$16.89</b>

Due to rounding, totals may not add up accurately.



# APPENDIX

2021 TOP 20 COMMERCIAL PMPM SPEND BY DRUG THERAPY CATEGORY *Figure 76*

Rank	Commercial Therapy	2020 PMPM	2021 PMPM	2020-21 % Change	% of Total PMPM	Cost Per Claim	Members/1K	Claims Per Member	2021 ASP Index*
1	Oncology	\$13.85	\$14.55	▲ 5.1%	39.1%	\$3,535	5.00	9.9	1.81
2	BDAID: Crohn's Disease/Ulcerative Colitis	\$3.64	\$3.73	▲ 2.4%	10.0%	\$6,761	1.26	5.3	1.67
3	Multiple Sclerosis	\$2.55	\$2.78	▲ 9.0%	7.5%	\$22,290	0.42	3.6	1.65
4	Immune Globulin	\$2.22	\$2.21	▼ -0.5%	5.9%	\$3,917	0.44	15.4	1.53
5	Colony-Stimulating Factors	\$2.06	\$1.84	▼ -10.5%	4.9%	\$4,281	1.04	4.9	2.42
6	BDAID: Rheumatoid Arthritis	\$1.25	\$1.21	▼ -3.5%	3.2%	\$4,247	0.55	6.2	1.31
7	Hematology	\$0.89	\$0.82	▼ -7.6%	2.2%	\$14,681	0.05	13.8	1.54
8	Ophthalmic Injections	\$0.70	\$0.72	▲ 2.9%	1.9%	\$1,047	1.69	4.9	1.15
9	Rare Disease	\$0.17	\$0.62	▲ 260.1%	1.7%	\$53,014	0.03	5.5	1.28
10	Contraceptives	\$0.53	\$0.58	▲ 9.3%	1.6%	\$708	7.73	1.3	1.33
11	Iron, Intravenous	\$0.48	\$0.58	▲ 21.3%	1.6%	\$691	3.36	3.0	2.00
12	Botulinum Toxins	\$0.46	\$0.51	▲ 10.2%	1.4%	\$1,290	1.87	2.5	1.31
13	Other	\$0.37	\$0.44	▲ 18.7%	1.2%	\$116	20.32	2.3	1.47
14	BDAID: Psoriasis/Psoriatic Arthritis	\$0.30	\$0.31	▲ 5.9%	0.8%	\$4,409	0.17	5.0	1.33
15	CNS Agents: Rare Diseases	\$0.30	\$0.30	▲ 3.3%	0.8%	\$15,989	0.01	22.9	1.27
16	Bone Resorption Inhibitors (Osteoporosis)	\$0.23	\$0.26	▲ 12.6%	0.7%	\$1,337	1.55	1.5	1.34
17	Viscosupplementation	\$0.21	\$0.23	▲ 11.0%	0.6%	\$414	2.72	2.5	1.25
18	BDAID: Systemic Lupus Erythematosus	\$0.16	\$0.18	▲ 13.2%	0.5%	\$3,659	0.06	9.3	1.20
19	BDAIDs: Other	\$0.15	\$0.16	▲ 6.6%	0.4%	\$5,113	0.08	4.5	2.09
20	Gout	\$0.15	\$0.16	▲ 5.4%	0.4%	\$26,564	0.01	7.8	1.31

\*ASP Index compares the unit cost on the claim to the ASP unit cost reported by CMS. Due to rounding, totals may not add up accurately.

# APPENDIX

2021 TOP 20 MEDICARE PMPM SPEND BY DRUG THERAPY CATEGORY *Figure 77*

Rank	Medicare Therapy	2020 PMPM	2021 PMPM	2020-21 % Change	% of Total PMPM	Cost Per Claim	Members/1K	Claims Per Member	2021 ASP Index*
1	Oncology	\$30.21	\$31.94	▲ 5.7%	53.2%	\$2,545	18.65	8.1	1.09
2	Ophthalmic Injections	\$6.96	\$6.99	▲ 0.5%	11.6%	\$775	20.32	5.3	1.08
3	Immune Globulin	\$2.13	\$2.44	▲ 14.4%	4.1%	\$2,400	0.91	13.4	1.16
4	Colony-Stimulating Factors	\$3.04	\$2.03	▼ -33.2%	3.4%	\$2,040	2.69	4.4	1.24
5	Bone Resorption Inhibitors (Osteoporosis)	\$1.33	\$1.61	▲ 20.7%	2.7%	\$942	13.72	1.5	1.09
6	Hematology	\$1.18	\$1.58	▲ 33.2%	2.6%	\$8,133	0.20	11.8	1.06
7	BDAID: Rheumatoid Arthritis	\$1.72	\$1.57	▼ -8.8%	2.6%	\$2,445	1.18	6.5	1.11
8	BDAID: Crohn's Disease/Ulcerative Colitis	\$1.07	\$1.19	▲ 11.7%	2.0%	\$3,909	0.70	5.2	1.15
9	Viscosupplementation	\$0.97	\$1.06	▲ 9.5%	1.8%	\$350	13.81	2.6	1.08
10	Rare Disease	\$0.43	\$0.96	▲ 124.7%	1.6%	\$21,129	0.08	6.6	1.07
11	Iron, Intravenous	\$0.68	\$0.81	▲ 20.2%	1.4%	\$412	6.94	3.4	1.11
12	Asthma/COPD	\$0.81	\$0.79	▼ -1.9%	1.3%	\$408	7.88	2.9	1.09
13	Botulinum Toxins	\$0.67	\$0.72	▲ 8.7%	1.2%	\$960	4.10	2.2	1.08
14	Other	\$0.51	\$0.56	▲ 10.4%	0.9%	\$55	48.42	2.6	1.12
15	Gastrointestinal: Chemoprotectant/Hormonal	\$0.66	\$0.54	▼ -19.3%	0.9%	\$4,378	0.20	7.4	1.11
16	Infectious Disease	\$0.28	\$0.30	▲ 5.0%	0.5%	\$53	34.16	1.9	1.17
17	Anticonvulsants	\$0.04	\$0.07	▲ 60.2%	0.1%	\$3,308	0.12	2.1	1.08
18	BDAIDs: Other	\$0.05	\$0.07	▲ 39.6%	0.1%	\$2,217	0.09	4.0	1.09
19	Transplant	\$0.04	\$0.06	▲ 37.5%	0.1%	\$313	0.16	14.8	1.16
20	Thyroid Agents	\$0.02	\$0.04	▲ 64.5%	0.1%	\$52	0.20	45.5	1.20

\*ASP Index compares the unit cost on the claim to the ASP unit cost reported by CMS. Due to rounding, totals may not add up accurately.

# APPENDIX

2021 TOP 20 MEDICAID PMPM SPEND BY DRUG THERAPY CATEGORY *Figure 78*

Rank	Medicaid Therapy	2020 PMPM	2021 PMPM	2020-21 % Change	% of Total PMPM	Cost Per Claim	Members/1K	Claims Per Member	2021 ASP Index <sup>2</sup>
1	Oncology	\$4.66	\$4.57	▼ -1.9%	27.0%	\$2,697	2.24	9.1	1.47
2	CNS Agents: Rare Diseases	\$0.98	\$0.81	▼ -17.3%	4.8%	\$44,332	0.03	8.6	1.20
3	BDAID: Crohn's Disease/Ulcerative Colitis	\$0.73	\$0.79	▲ 8.1%	4.7%	\$5,680	0.34	4.9	1.93
4	Rare Disease	\$0.14	\$0.78	▲ 436.3%	4.6%	\$111,623	0.01	6.3	1.10
5	Hematology	\$0.47	\$0.59	▲ 26.1%	3.5%	\$11,140	0.05	13.7	1.72
6	Immune Globulin	\$0.58	\$0.59	▲ 1.9%	3.5%	\$2,632	0.20	13.7	1.66
7	Multiple Sclerosis	\$0.49	\$0.56	▲ 14.9%	3.3%	\$12,895	0.15	3.6	1.37
8	Enzyme-Replacement Therapy	\$0.43	\$0.52	▲ 21.1%	3.1%	\$14,215	0.03	16.4	1.37
9	Colony-Stimulating Factors	\$0.61	\$0.45	▼ -25.7%	2.7%	\$3,142	0.42	4.1	2.15
10	Infectious Disease	\$0.39	\$0.40	▲ 2.8%	2.4%	\$139	17.72	2.0	1.54
11	Asthma/COPD	\$0.34	\$0.35	▲ 2.7%	2.1%	\$782	2.98	1.8	1.26
12	Other	\$0.26	\$0.29	▲ 10.3%	1.7%	\$136	12.34	2.1	1.44
13	Botulinum Toxins	\$0.24	\$0.26	▲ 6.8%	1.5%	\$1,341	1.03	2.3	1.24
14	Iron, Intravenous	\$0.20	\$0.25	▲ 28.6%	1.5%	\$626	2.10	2.3	1.61
15	BDAID: Rheumatoid Arthritis	\$0.25	\$0.23	▼ -9.5%	1.4%	\$3,478	0.15	5.1	1.51
16	Ophthalmic Injections	\$0.14	\$0.18	▲ 22.0%	1.0%	\$598	0.83	4.3	1.12
17	BDAID: Systemic Lupus Erythematosus	\$0.06	\$0.07	▲ 11.3%	0.4%	\$2,999	0.03	7.9	1.32
18	Erythropoiesis-Stimulating Agents	\$0.04	\$0.04	▲ 3.0%	0.2%	\$330	0.22	6.7	2.26
19	Gout	\$0.01	\$0.03	▲ 141.7%	0.2%	\$26,065	-	12.0	1.22
20	End-Stage Renal Disease: Erythropoiesis-Stimulating Agents	\$0.01	\$0.02	▲ 11.3%	0.1%	\$266	0.04	17.9	4.47

\*ASP Index compares the unit cost on the claim to the ASP unit cost reported by CMS.  
Due to rounding, totals may not add up accurately.

# APPENDIX

COMMERCIAL TOP 25 DRUG PMPM SPEND 2020-21\* *Figure 79*

Spend PMPM Rank	Trend Driver Rank**	HCPCS	Brand	PMPM			AVERAGE COST PER PATIENT			MEMBERS/1K		
				2020	2021	\$ Change	2020	2021	% Change	2020	2021	% Change
1	2	J9271	Keytruda	\$1.87	\$2.28	\$0.41	\$91,437	\$94,609	3.5%	0.245	0.289	17.9%
2	4	J2350	Ocrevus	\$1.73	\$1.97	\$0.24	\$77,890	\$79,660	2.3%	0.266	0.297	11.7%
3	7	J3380	Entyvio	\$1.41	\$1.58	\$0.17	\$41,315	\$41,994	1.6%	0.410	0.451	9.9%
4	6	Q5107	Mvasi	\$0.44	\$0.62	\$0.18	\$37,831	\$43,145	14.0%	0.140	0.172	22.8%
5	1	J9144	Darzalex Faspro	\$0.05	\$0.57	\$0.52	\$57,554	\$119,500	107.6%	0.010	0.057	453.2%
6	18	J0178	Eylea	\$0.45	\$0.51	\$0.06	\$11,017	\$11,303	2.6%	0.493	0.545	10.6%
7	16	J1569	Gammagard Liquid	\$0.44	\$0.51	\$0.06	\$49,569	\$54,923	10.8%	0.107	0.111	3.4%
8	3	J3241	Tepezza	\$0.11	\$0.49	\$0.37	\$191,622	\$281,503	46.9%	0.007	0.021	193.3%
9	12	Q5117	Kanjinti	\$0.40	\$0.48	\$0.09	\$36,048	\$36,709	1.8%	0.132	0.158	19.7%
10	15	J9354	Kadcyla	\$0.40	\$0.46	\$0.07	\$89,732	\$99,683	11.1%	0.053	0.056	5.0%
11	24	J3357	Stelara	\$0.39	\$0.44	\$0.05	\$56,100	\$59,274	5.7%	0.084	0.090	6.7%
12	19	J9022	Tecentriq	\$0.38	\$0.44	\$0.06	\$75,858	\$88,670	16.9%	0.060	0.059	-0.8%
13	25	J9042	Adcetris	\$0.33	\$0.38	\$0.05	\$171,117	\$189,248	10.6%	0.023	0.024	4.2%
14	5	Q5119	Ruxience	\$0.08	\$0.32	\$0.24	\$20,042	\$25,549	27.5%	0.051	0.150	196.9%
15	21	J1568	Octagam	\$0.23	\$0.29	\$0.06	\$38,415	\$42,529	10.7%	0.072	0.081	13.4%
16	22	Q5115	Truxima	\$0.19	\$0.27	\$0.08	\$30,275	\$29,512	-2.5%	0.076	0.111	46.0%
17	23	J1303	Ultomiris	\$0.20	\$0.25	\$0.05	\$402,433	\$366,002	-9.1%	0.006	0.008	37.2%
18	13	J7170	Hemlibra	\$0.17	\$0.25	\$0.08	\$346,537	\$406,152	17.2%	0.006	0.007	23.0%
19	8	Q5118	Zirabev	\$0.03	\$0.18	\$0.15	\$23,360	\$30,114	28.9%	0.015	0.073	384.9%
20	9	Q5116	Trazimera	\$0.03	\$0.15	\$0.13	\$22,356	\$30,445	36.2%	0.014	0.061	331.4%
21	11	J9358	Enhertu	\$0.04	\$0.13	\$0.09	\$72,065	\$93,817	30.2%	0.007	0.017	135.5%
22	10	J9317	Trodelyv	\$0.01	\$0.12	\$0.11	\$68,535	\$108,442	58.2%	0.002	0.014	696.1%
23	20	Q5114	Ogivri	\$0.05	\$0.11	\$0.06	\$57,439	\$82,528	43.7%	0.010	0.015	59.3%
24	14	J9316	Phesgo	-	\$0.08	\$0.08	-	\$68,782	-	-	0.013	-
25	17	Q5120	Ziextenzo	-	\$0.07	\$0.06	\$11,546	\$14,959	29.6%	0.004	0.053	1121.9%

\*New drugs may only reflect partial year of therapy (e.g., Darzalex Faspro, Phesgo, Zirabev).

\*\*Trend driver rank is based on total change from 2020-21.

# APPENDIX

MEDICARE TOP 25 DRUG PMPM SPEND 2020-21\* *Figure 80*

Spend PMPM Rank	Trend Driver Rank**	HCPCS	Brand	PMPM			AVERAGE COST PER PATIENT			MEMBERS/1K			
				2020	2021	\$ Change	2020	2021	% Change	2020	2021	% Change	
1	2	J9271	Keytruda	\$7.08	\$7.93	\$0.85	\$53,481	\$56,278	5.2%	1.588	1.691	6.5%	
2	6	J0178	Eylea	\$4.19	\$4.54	\$0.35	\$9,602	\$9,448	-1.6%	5.237	5.765	10.1%	
3	9	J0897	Xgeva/Prolia	\$2.30	\$2.43	\$0.13	\$2,635	\$2,558	-2.9%	10.475	11.408	8.9%	
4	4	J9022	Tecentriq	\$1.20	\$1.64	\$0.44	\$46,771	\$53,800	15.0%	0.309	0.367	18.8%	
5	1	J9144	Darzalex Faspro	\$0.08	\$1.61	\$1.53	\$22,222	\$70,610	217.8%	0.044	0.273	520.2%	
6	8	J1300	Soliris	\$0.90	\$1.14	\$0.24	\$409,796	\$451,291	10.1%	0.026	0.030	14.9%	
7	13	J9044	Velcade	\$0.67	\$0.85	\$0.18	\$18,244	\$21,214	16.3%	0.443	0.482	8.7%	
8	17	J1569	Gammagard Liquid	\$0.69	\$0.83	\$0.15	\$24,963	\$28,306	13.4%	0.331	0.354	7.0%	
9	11	Q5107	Mvasi	\$0.65	\$0.83	\$0.18	\$23,509	\$25,612	8.9%	0.333	0.391	17.3%	
10	20	J9228	Yervoy	\$0.71	\$0.83	\$0.12	\$51,313	\$53,316	3.9%	0.165	0.187	12.9%	
11	5	J3241	Tepezza	\$0.23	\$0.66	\$0.43	\$157,477	\$227,106	44.2%	0.018	0.035	96.9%	
12	25	Q5115	Truxima	\$0.53	\$0.65	\$0.13	\$19,122	\$16,475	-13.8%	0.331	0.475	43.7%	
13	10	J3380	Entyvio	\$0.46	\$0.65	\$0.19	\$25,637	\$25,814	0.7%	0.216	0.302	39.6%	
14	3	Q5119	Ruxience	\$0.11	\$0.57	\$0.46	\$12,157	\$14,997	23.4%	0.106	0.454	328.6%	
15	21	J1930	Somatuline Depot	\$0.34	\$0.45	\$0.12	\$47,317	\$49,264	4.1%	0.086	0.111	28.7%	
16	23	J9119	Libtayo	\$0.22	\$0.33	\$0.11	\$64,306	\$55,763	-13.3%	0.042	0.072	71.0%	
17	24	J0896	Reblozyl	\$0.20	\$0.30	\$0.11	\$81,841	\$75,898	-7.3%	0.029	0.048	66.6%	
18	7	Q5118	Zirabev	\$0.05	\$0.30	\$0.24	\$12,109	\$20,142	66.3%	0.053	0.176	232.2%	
19	19	J1568	Octagam	\$0.13	\$0.26	\$0.13	\$13,940	\$22,049	58.2%	0.110	0.141	28.0%	
20	12	Q2043	Provenge	\$0.04	\$0.22	\$0.18	\$68,246	\$109,342	60.2%	0.007	0.024	261.0%	
21	18	Q5116	Trazimera	\$0.04	\$0.17	\$0.13	\$13,109	\$21,823	66.5%	0.037	0.096	154.8%	
22	14	J9223	Zepzelca	-	\$0.17	\$0.17	-	\$38,316	-	-	-	0.054	-
23	15	J9317	Trodelyv	\$0.01	\$0.16	\$0.16	\$43,531	\$69,782	60.3%	0.002	0.028	1179.8%	
24	16	J1454	Akynzeo	-	\$0.16	\$0.16	\$804	\$2,712	237.2%	0.073	0.708	872.5%	
25	22	J9177	Padcev	\$0.04	\$0.15	\$0.11	\$39,985	\$63,141	57.9%	0.011	0.028	156.0%	

\*New drugs may only reflect partial year of therapy (e.g., Darzalex Faspro, Phesgo, Zirabev).

\*\*Trend driver rank is based on total change from 2020-21.

# APPENDIX

MEDICAID TOP 25 DRUG PMPM SPEND 2020-21\* *Figure 81*

Spend PMPM Rank	Trend Driver Rank**	HCPCS	Brand	PMPM			AVERAGE COST PER PATIENT			MEMBERS/1K		
				2020	2021	\$ Change	2020	2021	% Change	2020	2021	% Change
1	9	J9271	Keytruda	\$0.85	\$0.91	\$0.05	\$50,374	\$48,522	-3.7%	0.203	0.224	10.3%
2	16	J1300	Soliris	\$0.36	\$0.40	\$0.04	\$269,816	\$318,178	17.9%	0.016	0.015	-6.1%
3	5	J1428	Exondys	\$0.31	\$0.38	\$0.07	\$970,955	\$1,085,321	11.8%	0.004	0.004	9.5%
4	3	J2350	Ocrevus	\$0.27	\$0.36	\$0.09	\$45,779	\$47,055	2.8%	0.070	0.091	31.3%
5	6	J3380	Entyvio	\$0.20	\$0.27	\$0.07	\$36,072	\$40,241	11.6%	0.068	0.081	18.9%
6	1	J3399	Zolgensma	\$0.12	\$0.22	\$0.10	\$2,167,500	\$2,167,500	-	0.001	0.001	87.8%
7	14	J1439	Injectafer	\$0.15	\$0.20	\$0.04	\$1,901	\$2,171	14.2%	0.964	1.092	13.3%
8	23	J0690	Cefazolin	\$0.16	\$0.19	\$0.03	\$494	\$518	4.8%	3.886	4.338	11.6%
9	7	J9354	Kadcyla	\$0.11	\$0.17	\$0.05	\$42,897	\$54,542	27.1%	0.032	0.037	16.9%
10	2	Q5115	Truxima	\$0.05	\$0.15	\$0.10	\$16,939	\$26,463	56.2%	0.035	0.070	99.9%
11	17	J9173	Imfinzi	\$0.10	\$0.14	\$0.04	\$35,619	\$44,482	24.9%	0.034	0.038	9.8%
12	15	Q5107	Mvasi	\$0.10	\$0.14	\$0.04	\$22,497	\$26,675	18.6%	0.053	0.062	17.9%
13	24	J9228	Yervoy	\$0.08	\$0.11	\$0.03	\$49,288	\$60,074	21.9%	0.020	0.022	9.0%
14	4	J3241	Tepezza	\$0.02	\$0.11	\$0.08	\$150,589	\$268,252	78.1%	0.002	0.005	150.3%
15	10	J2796	Nplate	\$0.05	\$0.10	\$0.05	\$45,788	\$68,975	50.6%	0.014	0.018	29.6%
16	11	J0584	Crysvita	\$0.05	\$0.10	\$0.05	\$127,924	\$174,376	36.3%	0.005	0.007	47.5%
17	13	J1303	Ultomiris	\$0.04	\$0.09	\$0.05	\$133,025	\$193,918	45.8%	0.004	0.005	40.8%
18	19	J0221	Lumizyme	\$0.04	\$0.08	\$0.03	\$129,004	\$168,280	30.4%	0.004	0.005	40.8%
19	25	J3357	Stelara	\$0.05	\$0.08	\$0.03	\$51,982	\$65,824	26.6%	0.012	0.014	20.0%
20	21	Q9991	Sublocade	\$0.05	\$0.08	\$0.03	\$4,734	\$4,963	4.8%	0.115	0.183	58.9%
21	8	J9317	Trodelyv	\$0.01	\$0.06	\$0.05	\$116,321	\$79,021	-32.1%	0.001	0.009	1308.2%
22	12	J9144	Darzalex Faspro	-	\$0.05	\$0.05	\$23,810	\$32,802	37.8%	0.001	0.018	1261.2%
23	18	Q5118	Zirabev	\$0.01	\$0.05	\$0.04	\$15,743	\$17,339	10.1%	0.009	0.033	262.1%
24	20	Q5116	Trazimera	\$0.01	\$0.04	\$0.03	\$15,215	\$26,737	75.7%	0.005	0.017	228.6%
25	22	J9223	Zepzelca	-	\$0.03	\$0.03	-	\$55,738	-	-	0.006	-


\*New drugs may only reflect partial year of therapy (e.g., Darzalex Faspro, Phesgo, Zirabev).

\*\*Trend driver rank is based on total change from 2020-21.

# APPENDIX

2021 TOP 10 HIGHEST-COST MEDICAL BENEFIT DRUGS BY ALLOWED AMOUNT PER PATIENT\* *Figure 82*

● Commercial ● Medicare ● Medicaid



\*Drugs administered in the hospital inpatient setting are not included in analyses.

# APPENDIX


## 2021 MARKET SHARE TRENDS: RARE DISEASE\*\*

### Commercial *Figure 83*

● Tepezza ● Spinraza ● Exondys ● Zolgensma ● Radicava ● Reblozyl

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Tepezza	\$191,622	\$281,503
Spinraza	\$315,103	\$422,540
Exondys	\$993,407	\$1,651,382
Zolgensma	\$2,154,750	\$2,140,938
Radicava	\$86,497	\$97,338
Reblozyl	\$63,652	\$103,735

#### Allowed Amount PMPM



### Medicare *Figure 84*


● Tepezza ● Spinraza ● Exondys ● Zolgensma ● Radicava ● Reblozyl

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Tepezza	\$157,477	\$227,106
Spinraza	-	-
Exondys	-	-
Zolgensma	-	-
Radicava	\$90,910	\$83,846
Reblozyl	\$81,841	\$75,898

#### Allowed Amount PMPM



### Medicaid *Figure 85*

● Tepezza ● Spinraza ● Exondys ● Zolgensma ● Radicava ● Reblozyl

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Tepezza	\$150,589	\$268,252
Spinraza	\$363,232	\$262,337
Exondys	\$970,955	\$1,085,321
Zolgensma	\$2,167,500	\$2,167,500
Radicava	\$44,994	\$18,682
Reblozyl	\$12,903	\$50,130

#### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.



# APPENDIX

## 2021 MARKET SHARE TRENDS: SC AND IV IMMUNE GLOBULIN\*\*†

### Commercial Figure 86

● Gamunex-C/Gammaked ● Gammagard Liquid ● Privigen  
● Octagam ● Gammaplex ● Hizentra

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Gamunex-C/Gammaked	\$54,291	\$55,819
Gammagard Liquid	\$49,569	\$54,923
Privigen	\$58,195	\$56,845
Octagam	\$38,415	\$42,529
Gammaplex	\$91,824	\$85,222
Hizentra	\$58,444	\$56,160

#### Allowed Amount PMPM



### Medicare Figure 87

● Gamunex-C/Gammaked ● Gammagard Liquid ● Privigen  
● Octagam ● Gammaplex ● Hizentra

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Gamunex-C/Gammaked	\$25,966	\$31,726
Gammagard Liquid	\$24,963	\$28,306
Privigen	\$20,999	\$23,165
Octagam	\$13,940	\$22,049
Gammaplex	\$26,490	\$45,742
Hizentra	\$41,187	\$44,124

#### Allowed Amount PMPM



### Medicaid Figure 88


● Gamunex-C/Gammaked ● Gammagard Liquid ● Privigen  
● Octagam ● Gammaplex ● Hizentra

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Gamunex-C/Gammaked	\$29,502	\$32,911
Gammagard Liquid	\$31,890	\$30,324
Privigen	\$17,002	\$25,196
Octagam	\$52,227	\$49,408
Gammaplex	\$16,600	\$22,555
Hizentra	\$41,905	\$38,995

#### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.  
†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.  
Due to rounding, totals may not add up accurately.

# APPENDIX


## 2021 MARKET SHARE TRENDS: BDAIDS: CROHN'S DISEASE/UC\*†

### Commercial *Figure 89*


● Entyvio ● Remicade ● Stelara ● Inflectra ● Stelara IV ● Renflexis

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Entyvio	\$41,315	\$41,994
Remicade	\$32,673	\$29,835
Stelara	\$56,100	\$59,274
Inflectra	\$22,269	\$20,201
Stelara Iv	\$6,985	\$6,875
Renflexis	\$19,208	\$20,170

#### Allowed Amount PMPM




### Medicare *Figure 90*


● Entyvio ● Remicade ● Stelara ● Inflectra ● Stelara IV ● Renflexis

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Entyvio	\$25,637	\$25,814
Remicade	\$14,920	\$13,794
Stelara	\$40,007	\$28,144
Inflectra	\$13,670	\$11,622
Stelara Iv	\$3,671	\$4,810
Renflexis	\$9,830	\$7,101

#### Allowed Amount PMPM




### Medicaid *Figure 91*


● Entyvio ● Remicade ● Stelara ● Inflectra ● Stelara IV ● Renflexis

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Entyvio	\$36,072	\$40,241
Remicade	\$24,613	\$24,681
Stelara	\$51,982	\$65,824
Inflectra	\$13,353	\$12,265
Stelara Iv	\$6,196	\$5,656
Renflexis	\$12,590	\$5,070

#### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.  
 †Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.  
 Due to rounding, totals may not add up accurately.

# APPENDIX


## 2021 MARKET SHARE TRENDS: BDAIDS: RHEUMATOID ARTHRITIS\*†

### Commercial Figure 92


● Orencea ● Rituxan ● Remicade ● Simponi Aria ● Actemra ● Cimzia

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Orencea	\$34,137	\$32,048
Rituxan	\$34,050	\$34,459
Remicade	\$23,362	\$18,827
Simponi Aria	\$18,162	\$16,260
Actemra	\$24,674	\$26,132
Cimzia	\$24,432	\$21,865

#### Allowed Amount PMPM




### Medicare Figure 93


● Orencea ● Rituxan ● Remicade ● Simponi Aria ● Actemra ● Cimzia

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Orencea	\$29,084	\$25,666
Rituxan	\$17,530	\$16,531
Remicade	\$10,215	\$7,945
Simponi Aria	\$11,943	\$10,122
Actemra	\$12,845	\$17,096
Cimzia	\$18,329	\$22,174

#### Allowed Amount PMPM




### Medicaid Figure 94


● Orencea ● Rituxan ● Remicade ● Simponi Aria ● Actemra ● Cimzia

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Orencea	\$22,073	\$21,385
Rituxan	\$26,292	\$22,247
Remicade	\$17,368	\$17,199
Simponi Aria	\$14,637	\$10,400
Actemra	\$16,706	\$15,480
Cimzia	\$15,211	\$6,348

#### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.

# APPENDIX

## 2021 MARKET SHARE TRENDS: HEMATOLOGY\*\*†

### Commercial Figure 95

● Soliris ● Ultomiris ● Nplate ● Panhematin ● Kcentra

#### Market Share

2020



2021



#### Annual Cost per Patient

Brand	2020	2021
Soliris	\$456,204	\$445,504
Ultomiris	\$402,433	\$366,002
Nplate	\$68,332	\$67,664
Panhematin	\$101,497	\$228,925
Kcentra	\$7,682	\$12,092

### Medicare Figure 96


● Soliris ● Ultomiris ● Nplate ● Panhematin ● Kcentra

#### Market Share

2020



2021



#### Annual Cost per Patient


Brand	2020	2021
Soliris	\$409,796	\$451,291
Ultomiris	\$61,496	\$135,071
Nplate	\$31,927	\$43,508
Panhematin	-	-
Kcentra	\$3,924	\$4,914

### Medicaid Figure 97


● Soliris ● Ultomiris ● Nplate ● Panhematin ● Kcentra

#### Market Share

2020




2021




#### Annual Cost per Patient

Brand	2020	2021
Soliris	\$269,816	\$318,178
Ultomiris	\$133,025	\$193,918
Nplate	\$45,788	\$68,975
Panhematin	\$141,843	\$10,137
Kcentra	\$4,325	\$9,357


### Allowed Amount PMPM



### Allowed Amount PMPM



### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.  
 †Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.  
 Due to rounding, totals may not add up accurately.

# APPENDIX


## 2021 MARKET SHARE TRENDS: ONCOLOGY: BREAST CANCER\*\*†

### Commercial Figure 98


● Perjeta ● Kanjinti ● Kadcyła ● Keytruda ● Trazimera ● Herceptin  
● Faslodex

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Perjeta	\$45,707	\$46,182
Kanjinti	\$29,213	\$26,206
Kadcyła	\$64,415	\$69,212
Keytruda	\$48,546	\$48,194
Trazimera	\$18,807	\$23,643
Herceptin	\$43,778	\$39,741
Faslodex	\$12,374	\$10,018

#### Allowed Amount PMPM




### Medicare Figure 99


● Perjeta ● Kanjinti ● Kadcyła ● Keytruda ● Trazimera ● Herceptin  
● Faslodex

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Perjeta	\$32,480	\$37,768
Kanjinti	\$20,852	\$20,117
Kadcyła	\$33,312	\$34,805
Keytruda	\$27,983	\$25,133
Trazimera	\$12,882	\$22,366
Herceptin	\$31,259	\$35,967
Faslodex	\$6,636	\$4,804

#### Allowed Amount PMPM




### Medicaid Figure 100


● Perjeta ● Kanjinti ● Kadcyła ● Keytruda ● Trazimera ● Herceptin  
● Faslodex

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Perjeta	\$36,689	\$34,627
Kanjinti	\$22,027	\$22,384
Kadcyła	\$36,619	\$44,165
Keytruda	\$41,529	\$40,521
Trazimera	\$21,135	\$18,846
Herceptin	\$29,385	\$37,792
Faslodex	\$5,815	\$4,705

#### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.

# APPENDIX


## 2021 MARKET SHARE TRENDS: ONCOLOGY: LUNG CANCER\*\*

### Commercial Figure 101


● Keytruda ● Alimta ● Imfinzi ● Tecentriq ● Opdivo  
● Cyramza ● Yervoy ● Zepzelca

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Keytruda	\$70,399	\$75,008
Alimta	\$32,077	\$34,737
Imfinzi	\$60,140	\$59,748
Tecentriq	\$60,363	\$58,959
Opdivo	\$70,025	\$53,441
Cyramza	\$45,555	\$49,475
Yervoy	\$46,449	\$44,326
Zepzelca	-	\$41,427

#### Allowed Amount PMPM




### Medicare Figure 102


● Keytruda ● Alimta ● Imfinzi ● Tecentriq ● Opdivo  
● Cyramza ● Yervoy ● Zepzelca

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Keytruda	\$47,668	\$49,411
Alimta	\$20,398	\$19,600
Imfinzi	\$54,764	\$33,771
Tecentriq	\$39,277	\$43,575
Opdivo	\$45,781	\$42,901
Cyramza	\$25,274	\$34,368
Yervoy	\$18,288	\$25,700
Zepzelca	-	\$37,055

#### Allowed Amount PMPM




### Medicaid Figure 103


● Keytruda ● Alimta ● Imfinzi ● Tecentriq ● Opdivo  
● Cyramza ● Yervoy ● Zepzelca

#### Market Share

2020




2021



#### Annual Cost per Patient

Brand	2020	2021
Keytruda	\$38,166	\$45,613
Alimta	\$17,583	\$31,879
Imfinzi	\$41,113	\$39,422
Tecentriq	\$30,129	\$30,718
Opdivo	\$34,189	\$30,076
Cyramza	\$43,686	\$19,774
Yervoy	\$17,807	\$25,504
Zepzelca	-	\$79,674

#### Allowed Amount PMPM



\*Includes all lung cancer diagnoses (e.g., NSCLC, SCLC, etc.). Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.

# APPENDIX


## 2021 MARKET SHARE TRENDS: ONCOLOGY: MULTIPLE MYELOMA\*†

### Commercial Figure 104


● Darzalex Faspro ● Velcade ● Darzalex ● Kyprolis ● Emluciti ● Sarclisa

#### Market Share

2020




2021




#### Annual Cost per Patient

Brand	2020	2021
Darzalex Faspro	\$38,795	\$77,227
Velcade	\$23,958	\$25,857
Darzalex	\$84,260	\$69,579
Kyprolis	\$55,491	\$60,019
Emluciti	\$49,287	\$63,116
Sarclisa	\$19,330	\$52,898

#### Allowed Amount PMPM



2020



2021

### Medicare Figure 105


● Darzalex Faspro ● Velcade ● Darzalex ● Kyprolis ● Emluciti ● Sarclisa

#### Market Share

2020




2021




#### Annual Cost per Patient

Brand	2020	2021
Darzalex Faspro	\$21,415	\$57,356
Velcade	\$14,941	\$16,512
Darzalex	\$47,461	\$43,647
Kyprolis	\$39,611	\$30,884
Emluciti	\$56,565	\$30,965
Sarclisa	-	\$27,437

#### Allowed Amount PMPM



2020



2021

### Medicaid Figure 106


● Darzalex Faspro ● Velcade ● Darzalex ● Kyprolis ● Emluciti ● Sarclisa

#### Market Share

2020




2021




#### Annual Cost per Patient

Brand	2020	2021
Darzalex Faspro	-	\$21,975
Velcade	\$15,386	\$14,446
Darzalex	\$42,971	\$21,044
Kyprolis	\$41,423	\$28,353
Emluciti	\$16,909	\$19,064
Sarclisa	-	-

#### Allowed Amount PMPM



2020



2021

\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.

# APPENDIX

## 2021 MARKET SHARE TRENDS: ONCOLOGY SUPPORT: SHORT-ACTING COLONY-STIMULATING FACTORS\*\*†

### Commercial *Figure 107*

Zarxio Neupogen Granix Nivestym

#### Market Share

2020



2021



#### Annual Cost per Patient


Brand	2020	2021
Zarxio	\$3,781	\$3,410
Neupogen	\$3,827	\$3,393
Granix	\$2,170	\$1,784
Nivestym	\$2,324	\$1,776

### Medicare *Figure 108*

Zarxio Neupogen Granix Nivestym

#### Market Share

2020



2021



#### Annual Cost per Patient

Brand	2020	2021
Zarxio	\$1,488	\$1,300
Neupogen	\$2,380	\$2,216
Granix	\$1,341	\$971
Nivestym	\$516	\$158

### Medicaid *Figure 109*

Zarxio Neupogen Granix Nivestym

#### Market Share

2020




2021




#### Annual Cost per Patient

Brand	2020	2021
Zarxio	\$1,186	\$1,523
Neupogen	\$3,494	\$1,902
Granix	\$803	\$2,087
Nivestym	\$1,651	\$2,557

### Allowed Amount PMPM




2020




2021

### Allowed Amount PMPM




2020




2021

### Allowed Amount PMPM



2020



2021

\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.



# APPENDIX

## 2021 MARKET SHARE TRENDS: ONCOLOGY SUPPORT: LONG-ACTING COLONY-STIMULATING FACTORS\*†

**Commercial** *Figure 110*

● Neulasta ● Udenyca ● Ziextenzo ● Fulphila ● Nyvepria

### Market Share

2020



2021



### Annual Cost per Patient

Brand	2020	2021
Neulasta	\$26,675	\$25,123
Udenyca	\$21,132	\$19,651
Ziextenzo	\$11,546	\$14,959
Fulphila	\$22,982	\$20,011
Nyvepria	-	\$15,065

**Medicare** *Figure 111*

● Neulasta ● Udenyca ● Ziextenzo ● Fulphila ● Nyvepria

### Market Share

2020



2021



### Annual Cost per Patient

Brand	2020	2021
Neulasta	\$14,537	\$10,356
Udenyca	\$10,185	\$9,603
Ziextenzo	\$2,803	\$5,981
Fulphila	\$7,703	\$8,374
Nyvepria	-	\$15,321

**Medicaid** *Figure 112*

● Neulasta ● Udenyca ● Ziextenzo ● Fulphila ● Nyvepria

### Market Share

2020




2021




### Annual Cost per Patient

Brand	2020	2021
Neulasta	\$17,934	\$16,516
Udenyca	\$9,455	\$12,500
Ziextenzo	\$11,433	\$6,741
Fulphila	\$8,360	\$9,785
Nyvepria	-	-


### Allowed Amount PMPM



### Allowed Amount PMPM



### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.

†Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.

Due to rounding, totals may not add up accurately.


# APPENDIX

## 2021 MARKET SHARE TRENDS: OPHTHALMIC INJECTIONS\*\*†‡


### Commercial Figure 113

● Eylea ● Lucentis ● Avastin ● Ozurdex ● Unclassified  
● Iluvien ● Beovu ● Visudyne

#### Market Share 2020




#### Market Share 2021



### Annual Cost per Patient

Brand	2020	2021
Eylea	\$11,017	\$11,303
Lucentis	\$7,572	\$7,460
Avastin	\$470	\$518
Ozurdex	\$3,380	\$3,373
Unclassified	\$675	\$724
Iluvien	\$12,823	\$11,941
Beovu	\$6,515	\$8,770
Visudyne	\$2,121	\$2,212


### Allowed Amount PMPM




### Medicare Figure 114

● Eylea ● Lucentis ● Avastin ● Ozurdex ● Unclassified  
● Iluvien ● Beovu ● Visudyne

#### Market Share 2020




#### Market Share 2021



### Annual Cost per Patient

Brand	2020	2021
Eylea	\$9,602	\$9,448
Lucentis	\$9,194	\$8,918
Avastin	\$346	\$318
Ozurdex	\$2,615	\$2,932
Unclassified	\$275	\$26
Iluvien	\$13,601	\$10,883
Beovu	\$4,928	\$8,062
Visudyne	\$1,765	\$1,633


### Allowed Amount PMPM




### Medicaid Figure 115

● Eylea ● Lucentis ● Avastin ● Ozurdex ● Unclassified  
● Iluvien ● Beovu ● Visudyne

#### Market Share 2020




#### Market Share 2021



### Annual Cost per Patient

Brand	2020	2021
Eylea	\$7,565	\$8,348
Lucentis	\$5,835	\$6,222
Avastin	\$408	\$425
Ozurdex	\$3,631	\$3,014
Unclassified	\$4,863	\$1,564
Iluvien	\$18,660	\$10,560
Beovu	-	-
Visudyne	-	\$1,661

### Allowed Amount PMPM



\*Only drugs with \$0.01 PMPM or greater were included in market share analysis.  
 †Claims that were outliers due to unusual dosing during the pandemic were excluded from market share analysis.  
 ‡Avastin may be billed using an unclassified code for ophthalmic indications.  
 Due to rounding, totals may not add up accurately.

# APPENDIX

2021 COMMERCIAL TOP 25 DRUG PMPM SPEND BY SITE OF SERVICE *Figure 116*

HCPCS	Brand	PMPM			COST PER CLAIM			MARKET SHARE		
		HOME	HOSPITAL OP	PHYSICIAN	HOME	HOSPITAL OP	PHYSICIAN	HOME	HOSPITAL OP	PHYSICIAN
J9271	Keytruda	-	\$1.48	\$0.80	-	\$20,381	\$12,298	-	53%	47%
J2350	Ocrevus	\$0.08	\$1.13	\$0.76	\$32,877	\$58,903	\$33,107	6%	42%	52%
J3380	Entyvio	\$0.33	\$0.49	\$0.76	\$7,380	\$11,339	\$6,758	22%	22%	56%
Q5107	Mvasi	-	\$0.46	\$0.16	\$414	\$7,067	\$3,373	-	57%	43%
J9144	Darzalex Faspro	-	\$0.39	\$0.18	\$8,122	\$15,666	\$9,097	-	56%	43%
J0178	Eylea	-	\$0.02	\$0.49	\$2,498	\$3,859	\$2,096	-	3%	97%
J1569	Gammagard Liquid	\$0.21	\$0.16	\$0.14	\$4,155	\$4,832	\$4,423	33%	35%	31%
J3241	Tepezza	\$0.11	\$0.12	\$0.26	\$51,778	\$79,461	\$56,039	28%	17%	55%
Q5117	Kanjinti	-	\$0.31	\$0.18	-	\$6,339	\$3,216	-	47%	53%
J9354	Kadcyla	-	\$0.31	\$0.15	-	\$14,867	\$9,529	-	54%	46%
J3357	Stelara	\$0.12	\$0.04	\$0.28	\$21,781	\$26,940	\$15,465	23%	5%	72%
J9022	Tecentriq	-	\$0.28	\$0.16	-	\$18,282	\$10,206	-	48%	52%
J9042	Adcetris	-	\$0.26	\$0.11	\$20,665	\$38,093	\$25,410	1%	60%	39%
Q5119	Ruxience	-	\$0.15	\$0.17	\$8,390	\$8,630	\$4,437	1%	40%	60%
J1568	Octagam	\$0.09	\$0.02	\$0.18	\$6,303	\$5,063	\$3,473	22%	6%	73%
Q5115	Truxima	-	\$0.22	\$0.05	\$7,620	\$8,310	\$5,501	-	70%	30%
J1303	Ultomiris	\$0.04	\$0.12	\$0.09	\$54,548	\$112,939	\$69,304	19%	44%	37%
J7170	Hemlibra	\$0.23	\$0.02	-	\$32,514	\$64,717	\$24,688	84%	11%	5%
Q5118	Zirabev	-	\$0.08	\$0.11	\$5,028	\$5,069	\$3,517	-	36%	64%
Q5116	Trazimera	-	\$0.07	\$0.09	\$11,990	\$5,593	\$3,437	-	32%	68%
J9358	Enhertu	-	\$0.08	\$0.05	\$11,658	\$18,421	\$10,946	1%	51%	49%
J9317	Trodelyv	-	\$0.09	\$0.04	-	\$15,354	\$10,187	-	61%	39%
Q5114	Ogivri	-	\$0.10	\$0.01	-	\$11,495	\$4,380	-	81%	19%
J9316	Phesgo	-	\$0.06	\$0.02	\$3,469	\$14,594	\$9,498	1%	67%	32%
Q5120	Ziextenzo	-	\$0.02	\$0.04	\$3,526	\$5,760	\$3,726	2%	30%	68%

# APPENDIX

2021 MEDICARE TOP 25 DRUG PMPM SPEND BY SITE OF SERVICE *Figure 117*

HCPCS	Brand	PMPM			COST PER CLAIM			MARKET SHARE		
		HOME	HOSPITAL OP	PHYSICIAN	HOME	HOSPITAL OP	PHYSICIAN	HOME	HOSPITAL OP	PHYSICIAN
J9271	Keytruda	-	\$5.09	\$2.84	-	\$9,941	\$10,672	-	64%	36%
J0178	Eylea	-	\$0.34	\$4.20	\$2,636	\$1,814	\$1,753	-	10%	90%
J0897	Xgeva/Prolia	\$0.01	\$0.90	\$1.52	\$1,360	\$1,392	\$1,335	1%	33%	66%
J9022	Tecentriq	-	\$1.00	\$0.65	-	\$8,983	\$8,638	-	63%	37%
J9144	Darzalex Faspro	-	\$0.96	\$0.65	-	\$7,747	\$7,465	-	57%	43%
J1300	Soliris	\$0.09	\$0.41	\$0.64	\$27,603	\$19,530	\$27,290	6%	50%	44%
J9044	Velcade	-	\$0.50	\$0.35	-	\$1,127	\$1,439	-	56%	44%
J1569	Gammagard Liquid	\$0.24	\$0.38	\$0.21	\$3,733	\$2,183	\$3,217	13%	61%	26%
Q5107	Mvasi	-	\$0.48	\$0.35	-	\$3,410	\$2,881	-	50%	50%
J9228	Yervoy	-	\$0.52	\$0.31	-	\$17,893	\$18,322	-	57%	43%
J3241	Tepezza	\$0.02	\$0.07	\$0.56	\$31,588	\$20,567	\$49,469	6%	24%	71%
Q5115	Truxima	-	\$0.43	\$0.23	-	\$3,089	\$3,657	-	62%	38%
J3380	Entyvio	\$0.06	\$0.30	\$0.29	\$6,285	\$5,278	\$5,881	10%	47%	44%
Q5119	Ruxience	-	\$0.29	\$0.27	-	\$3,462	\$3,277	-	54%	46%
J1930	Somatuline Depot	-	\$0.21	\$0.24	-	\$7,607	\$5,658	-	37%	63%
J9119	Libtayo	-	\$0.17	\$0.16	-	\$9,742	\$8,952	-	50%	50%
J0896	Reblozyl	-	\$0.11	\$0.20	-	\$8,521	\$11,269	-	50%	50%
Q5118	Zirabev	-	\$0.19	\$0.10	-	\$3,556	\$3,300	-	71%	29%
J1568	Octagam	\$0.02	\$0.04	\$0.21	\$9,187	\$2,757	\$2,372	1%	12%	87%
Q2043	Provenge	-	-	\$0.22	-	-	\$36,447	-	-	100%
Q5116	Trazimera	-	\$0.11	\$0.07	-	\$2,929	\$2,358	-	57%	43%
J9223	Zepzelca	-	\$0.08	\$0.09	-	\$11,842	\$12,994	-	56%	44%
J9317	Trodelyv	-	\$0.11	\$0.05	-	\$6,041	\$8,082	-	77%	23%
J1454	Akynzeo	-	\$0.01	\$0.15	\$300	\$556	\$597	2%	4%	94%
J9177	Padcev	-	\$0.06	\$0.08	-	\$3,964	\$7,200	-	69%	31%

# APPENDIX

2021 MEDICAID TOP 25 DRUG PMPM SPEND BY SITE OF SERVICE *Figure 118*


HCPCS	Brand	PMPM			COST PER CLAIM			MARKET SHARE		
		HOME	HOSPITAL OP	PHYSICIAN	HOME	HOSPITAL OP	PHYSICIAN	HOME	HOSPITAL OP	PHYSICIAN
J9271	Keytruda	-	\$0.65	\$0.26	-	\$10,717	\$10,352	-	75%	25%
J1300	Soliris	-	\$0.29	\$0.11	\$6,902	\$32,097	\$28,194	4%	77%	19%
J1428	Exondys	\$0.38	-	-	\$30,883	-	-	100%	-	-
J2350	Ocrevus	\$0.04	\$0.24	\$0.07	\$33,545	\$24,407	\$30,891	10%	73%	17%
J3380	Entyvio	\$0.03	\$0.18	\$0.07	\$6,507	\$9,358	\$6,673	13%	58%	29%
J3399	Zolgensma	-	\$0.22	-	-	\$2,167,500	-	-	67%	33%
J1439	Injectafer	-	\$0.12	\$0.08	\$948	\$1,171	\$921	1%	57%	42%
J0690	Cefazolin	-	\$0.19	-	\$38	\$407	\$4	1%	95%	4%
J9354	Kadcyla	-	\$0.09	\$0.08	-	\$7,050	\$10,205	-	56%	44%
Q5115	Truxima	-	\$0.13	\$0.02	-	\$5,781	\$5,910	-	85%	15%
J9173	Imfinzi	-	\$0.09	\$0.05	-	\$5,781	\$8,126	-	68%	32%
Q5107	Mvasi	-	\$0.07	\$0.07	-	\$3,449	\$3,522	-	44%	56%
J9228	Yervoy	-	\$0.09	\$0.02	-	\$25,481	\$23,971	-	72%	28%
J3241	Tepezza	\$0.07	\$0.03	\$0.01	\$52,814	\$71,400	\$61,020	44%	22%	33%
J2796	Nplate	-	\$0.09	\$0.01	-	\$4,201	\$2,812	-	69%	31%
J0584	Crysvita	\$0.10	-	-	\$18,991	-	-	100%	-	-
J1303	Ultomiris	-	\$0.08	\$0.01	-	\$56,846	\$76,781	-	90%	10%
J0221	Lumizyme	\$0.01	\$0.06	-	\$21,248	\$10,234	-	22%	78%	-
J3357	Stelara	-	\$0.06	\$0.01	\$16,547	\$25,571	\$10,647	4%	57%	39%
Q9991	Sublocade	-	-	\$0.07	-	\$2,527	\$1,623	-	4%	96%
J9317	Trodelvy	-	\$0.03	\$0.03	-	\$13,254	\$11,247	-	60%	40%
J9144	Darzalex Faspro	-	\$0.03	\$0.01	-	\$5,308	\$8,706	-	90%	10%
Q5118	Zirabev	-	\$0.04	-	-	\$2,465	\$5,082	-	93%	7%
Q5116	Trazimera	-	\$0.03	\$0.01	-	\$4,942	\$2,063	-	64%	36%
J9223	Zepzelca	-	\$0.01	\$0.01	-	\$15,854	\$14,393	-	70%	30%

# APPENDIX


## 2021 BIOSIMILAR MARKET SHARE\*

Commercial Medicare Medicaid Biosimilar Reference Product


### Bevacizumab Drug Group\*\* Figure 119




### Trastuzumab Drug Group Figure 120



### Pegfilgrastim Drug Group Figure 121



### Filgrastim Drug Group Figure 122



\*Based on units.

\*\*Bevacizumab market share reflects oncology indication only.


Totals may not add up to 100% because drugs with less than 5% of market share are excluded from the graphics.

# APPENDIX


## 2021 BIOSIMILAR MARKET SHARE\*

Commercial Medicare Medicaid Biosimilar Reference Product


### Epoetin Alfa Drug Group *Figure 123*



### Rituximab Drug Group\*\* *Figure 124*



### Infliximab Drug Group *Figure 125*



\*Based on units.

\*\*Rituximab market share reflects oncology indication only.

Totals may not add up to 100% because drugs with less than 5% of market share are excluded from the graphics.

# APPENDIX

2020 HOSPITAL ADMINISTRATION CODE TRENDS BY LOB *Figure 126*

CPT	DESCRIPTION	COMMERCIAL		MEDICARE		MEDICAID	
		PMPM	UNIT COST	PMPM	UNIT COST	PMPM	UNIT COST
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$0.75	\$715.82	\$1.36	\$382.85	\$0.08	\$255.73
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$0.42	\$475.73	\$0.58	\$222.19	\$0.05	\$86.80
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$0.11	\$192.48	\$0.09	\$59.23	\$0.03	\$29.68
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered	-	\$66.20	-	-	\$0.03	\$139.27
96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug	\$0.36	\$300.43	\$0.21	\$65.05	\$0.04	\$38.84
96361	Intravenous infusion, hydration; each additional hour	\$0.39	\$421.50	\$0.20	\$106.59	\$0.04	\$47.01
20610	Under general introduction or removal procedures on the musculoskeletal system	\$0.04	\$516.84	\$0.17	\$159.66	-	\$98.10
95165	Supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)	-	\$597.26	-	\$423.15	-	\$625.63
90471	Immunization administration through 18 years of age via any route of administration; first or only component of each vaccine or toxoid administered	\$0.02	\$94.56	\$0.02	\$37.53	-	\$10.03
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$0.27	\$318.60	\$0.64	\$191.06	\$0.08	\$61.05
90461	Immunization administration each additional component	-	\$83.74	-	-	\$0.01	\$106.50
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	\$0.15	\$420.36	\$0.18	\$199.44	\$0.02	\$69.88
96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour	\$0.10	\$291.72	\$0.16	\$139.05	\$0.17	\$670.94
96415	Chemotherapy administration, intravenous infusion technique; each additional hour	\$0.12	\$384.53	\$0.06	\$95.76	\$0.01	\$70.58
67028	Intravitreal injection of a pharmacologic agent (separate procedure)	\$0.03	\$962.76	\$0.17	\$236.62	-	\$214.84
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour	\$0.09	\$334.94	\$0.05	\$77.39	\$0.01	\$119.83
96366	Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour	\$0.11	\$400.71	\$0.09	\$106.30	\$0.01	\$74.65
96401	Chemotherapy administration, subcutaneous, or intramuscular; nonhormonal antineoplastic	\$0.03	\$320.26	\$0.05	\$174.83	-	\$93.50
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	\$0.06	\$638.65	\$0.03	\$306.69	-	\$203.09
95117	Immunotherapy injections	\$0.01	\$128.88	-	\$37.18	-	\$30.26
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug	\$0.05	\$359.65	\$0.02	\$79.67	-	\$107.14
90472	Immunization administration through 18 years of age via any route of administration	-	\$66.77	-	\$30.02	-	\$20.63
96402	Chemotherapy administration, subcutaneous, or intramuscular; hormonal antineoplastic	\$0.03	\$276.64	\$0.02	\$136.51	-	\$69.19
96409	Chemotherapy administration; intravenous, push technique; single or initial substance/drug	\$0.03	\$470.36	\$0.06	\$273.28	\$0.01	\$181.21
96376	Intravenous push, single or initial substance/drug; each additional sequential intravenous push of the same substance/drug provided in a facility	\$0.03	\$211.00	\$0.02	\$108.91	\$0.01	\$23.55
96368	Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion	\$0.02	\$179.47	-	\$68.23	-	\$20.70
96450	Chemotherapy administration, into CNS (e.g., intrathecal), requiring and including spinal puncture	\$0.02	\$898.25	-	\$219.69	-	\$231.51



# APPENDIX

2020 PHYSICIAN OFFICE ADMINISTRATION CODE TRENDS BY LOB *Figure 127*

CPT	DESCRIPTION	COMMERCIAL		MEDICARE		MEDICAID	
		PMPM	UNIT COST	PMPM	UNIT COST	PMPM	UNIT COST
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	\$0.36	\$240.83	\$0.37	\$137.97	\$0.03	\$123.13
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour	\$0.12	\$109.23	\$0.12	\$70.04	\$0.01	\$52.25
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	\$0.32	\$28.73	\$0.25	\$14.19	\$0.08	\$20.09
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified healthcare professional; first or only component of each vaccine or toxoid administered	\$0.42	\$40.57	-	-	\$0.50	\$47.41
96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug	\$0.05	\$61.59	\$0.03	\$24.71	-	\$25.73
96361	Intravenous infusion, hydration; each additional hour	\$0.01	\$38.16	\$0.01	\$18.32	-	\$17.10
20610	Under general introduction or removal procedures on the musculoskeletal system	\$0.34	\$112.51	\$0.56	\$63.69	\$0.03	\$82.64
95165	Supervision of preparation and provision of antigens for allergen immunotherapy; single or multiple antigens (specify number of doses)	\$0.36	\$288.10	\$0.02	\$183.62	-	\$205.37
90471	Immunization administration through 18 years of age via any route of administration; first or only component of each vaccine or toxoid administered	\$0.29	\$24.48	\$0.09	\$19.24	\$0.03	\$9.12
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug	\$0.02	\$83.94	\$0.01	\$39.76	-	\$40.68
90461	Immunization administration each additional component	\$0.18	\$39.08	-	-	\$0.04	\$111.54
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	\$0.02	\$80.37	\$0.01	\$33.68	-	\$45.54
96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour	\$0.06	\$83.12	\$0.07	\$40.47	\$0.04	\$181.43
96415	Chemotherapy administration, intravenous infusion technique; each additional hour	\$0.04	\$72.40	\$0.04	\$46.02	-	\$43.28
67028	Intravitreal injection of a pharmacologic agent (separate procedure)	\$0.13	\$197.56	\$0.95	\$130.67	\$0.03	\$302.10
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour	\$0.05	\$160.85	\$0.05	\$74.38	-	\$76.07
96366	Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour	\$0.02	\$57.36	\$0.01	\$30.15	-	\$23.66
96401	Chemotherapy administration, subcutaneous or intramuscular; nonhormonal antineoplastic	\$0.06	\$116.07	\$0.08	\$90.21	-	\$46.04
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	\$0.03	\$280.63	\$0.01	\$141.71	-	\$146.88
95117	Immunotherapy injections	\$0.08	\$14.76	\$0.01	\$10.64	-	\$14.57
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug	\$0.02	\$131.13	\$0.02	\$63.03	-	\$56.92
90472	Immunization administration through 18 years of age via any route of administration	\$0.04	\$23.51	-	\$14.49	\$0.01	\$14.90
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal antineoplastic	\$0.01	\$66.58	\$0.02	\$35.03	-	\$39.21
96409	Chemotherapy administration; intravenous, push technique; single or initial substance/drug	\$0.01	\$197.84	\$0.01	\$108.73	-	\$91.54
96376	Intravenous push, single or initial substance/drug; each additional sequential intravenous push of the same substance/drug provided in a facility	-	\$79.80	-	-	-	-
96368	Intravenous infusion for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion	-	\$34.35	\$0.01	\$20.01	-	\$16.68
96450	Chemotherapy administration, into CNS (e.g., intrathecal), requiring and including spinal puncture	-	\$335.39	-	\$158.77	-	\$237.46

# GLOSSARY

---

ASP.....	average sales price	MS.....	multiple sclerosis
BDAIDs.....	biologic drugs for autoimmune disorders	NDC.....	National Drug Code
CAR-T.....	chimeric antigen receptor T-cell therapy	PA.....	prior authorization
COPD.....	chronic obstructive pulmonary disease	PMPM.....	per member per month
COVID-19.....	coronavirus disease of 2019	PSCE.....	post-service claim edits
Crohn's/UC.....	Crohn's Disease/ulcerative colitis	RA.....	rheumatoid arthritis
CSF.....	colony-stimulating factors	SLE.....	systemic lupus erythematosus
ESA.....	erythropoiesis-stimulating agent	SOS.....	site of service
FDA.....	U.S. Food and Drug Administration	SC.....	subcutaneous
HCPCS.....	Healthcare Common Procedure Coding System	UC.....	ulcerative colitis
HOP.....	hospital outpatient	UM.....	utilization management
IV.....	intravenous	WAC.....	wholesale acquisition cost
LOB.....	line of business		

